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Abstract
 
Neutrophil migration across mucosal epithelium during inflammatory episodes involves the
precise orchestration of a number a cell surface molecules and signaling pathways. After successful
migration to the apical epithelial surface, apically localized epithelial proteins may serve to retain
PMN at the lumenal surface. At present, identification of apical epithelial ligands and their
PMN counter-receptors remain elusive. Therefore, to define the existence of apical epithelial
cell surface proteins involved in PMN–epithelial interactions, we screened a panel of antibodies
directed against epithelial plasma membranes. This strategy identified one antibody (OE-1) that
both localized to the apical cell membrane and significantly inhibited PMN transmigration
across epithelial monolayers. Microsequence analysis revealed that OE-1 recognized human
decay-accelerating factor (DAF, CD55). DAF is a highly glycosylated, 70–80-kD, glycosyl-
phosphatidyinositol–linked protein that functions predominantly as an inhibitor of autologous
complement lysis. DAF suppression experiments using antisense oligonucleotides or RNA
interference revealed that DAF may function as an antiadhesive molecule promoting the release
of PMN from the lumenal surface after transmigration. Similarly, peptides corresponding to the
antigen recognition domain of OE-1 resulted in accumulation of PMN on the apical epithelial
surface. The elucidation of DAF as an apical epithelial ligand for PMN provides a target for
novel anti-inflammatory therapies directed at quelling unwanted inflammatory episodes.
Key words: mimetic • inﬂammation • endothelia • antibody • phage display
 
Introduction
 
Neutrophils (PMN) are the first line of host defense against
bacterial pathogens. The majority of pathogens are encoun-
tered at mucosal surfaces, and identification of pathways
that elicit effective PMN mobilization to the epithelium
has been an area of active investigation. To engage pathogens
at sites of inflammation, PMN must first migrate out of cir-
culation through the endothelial cell layer and into host tissue.
Infections involving mucosal epithelial surfaces (intestine,
lung, oral cavity) require that PMN migrate to epithelium
in response to tissue-derived signals. Migration of PMN
through epithelial barriers involves a concerted series of cell
surface crosstalk events between the PMN and epithelial
cell. Evidence exists that initial PMN–epithelial binding
 
requires PMN 
 
 
 
2
 
 integrins (especially CD11b/18; reference
1), and that subsequent movement of PMN through the
paracellular space is dependent on epithelial CD47 interactions
with PMN-expressed signal regulatory protein 
 
 
 
 (Sirp
 
 
 
;
reference 2).
A critical site for PMN–pathogen interactions is the apical
epithelial membrane, and this membrane domain represents
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 ANOVA, analysis of variance; CHO, Chinese
hamster ovary; DAF, decay-accelerating factor; fMLP, 
 
n
 
-formyl-methionyl-
leucyl-phenylalanine; GPI, glycosyl-phosphatidyinositol; HMVEC, human
microvascular endothelial cells; ICAM-1, intercellular adhesion molecule 1;
PE-CAM, platelet-endothelial cell adhesion molecule; RFU, relative fluores-
cence units; SCR, short consensus repeats; Sirp
 
 
 
, signal regulatory protein 
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the terminal stage for migrating PMN (1). Moreover, a his-
topathological hallmark of many mucosal inflammatory dis-
eases is the formation of crypt abscesses, defined as the mi-
gration of large numbers of PMN across the apical
epithelial surface and into the lumenal aspect of the tissue
(3). Such observations suggest that PMN utilize apical epi-
thelial ligands to accomplish this task, yet apical ligands
have not been studied in detail. Some evidence indicates
that under certain circumstances (e.g., inflammatory bowel
diseases), intercellular adhesion molecule 1 (ICAM-1) is
expressed on the apical epithelial surface (4, 5) and can
serve as an apical retention signal for PMN on the epithe-
lium (5). Moreover, recent work has demonstrated that
PMN Fc receptor binding to epithelial-bound antibody
may contribute to the localization and retention of PMN
on the apical membrane (6). At present, it is not known
what molecular triggers might promote the dislocation of
PMN from the epithelial surface.
Here, we sought to identify other apical epithelial
ligands important in final stages of PMN transmigration.
To do this, we screened a panel of monoclonal antibodies
generated to epithelial plasma membrane antigen. This
screen identified 1 mAb, termed OE-1, which recognized
an apical epitope and inhibited physiologically directed
PMN transmigration. Extensions of these observations
identified the OE-1 antigen as decay-accelerating factor
(DAF), a glycosyl-phosphatidyinositol (GPI)–link 
 
 
 
80-kD
protein originally described as an inhibitor of autologous
complement lysis (7). Subsequent studies revealed that
DAF appears to function as an antiadhesive surface glyco-
protein that regulates the rate of PMN migration across the
apical epithelial membrane.
 
Materials and Methods
 
Cell Culture. 
 
T84, Caco2, and KB cells were grown on per-
meable 0.33-cm
 
2
 
 ring-supported polycarbonate filters (0.4-
 
 
 
m
pore size; Costar Corp.) or plastic polystyrene tissue culture dishes
(Costar Corp.), as indicated, using techniques described previ-
ously (8–10). To plate inverted inserts, transwell inserts were
placed upside down in a large petri dish and 80 
 
 
 
l of cell suspen-
sion was plated on each insert. The inserts were incubated over-
night at 37
 
 
 
C in a humidified incubator with 5% CO
 
2
 
. The fol-
lowing day, the inserts were flipped into DMEM supplemented
with 20% FBS. Where indicated, human microvascular endothe-
lial cells (HMVEC) were cultured as described previously (11).
The nontransformed human oral keratinocyte cell line OKF6 was
grown as described previously (12).
 
Human Neutrophil Isolation. 
 
PMN were freshly isolated from
whole blood obtained by venipuncture from healthy human do-
nors and anticoagulated with acid citrate dextrose as described
previously (13). In brief, plasma and mononuclear cells were re-
moved by aspiration from the buffy coat after centrifugation (400
 
 
 
g
 
;
20 min) at room temperature. RBCs were sedimented using 2%
gelatin, and residual RBCs were removed by lysis in ice-cold
NH
 
4
 
Cl buffer. PMN were 
 
 
 
90% pure as determined by micro-
scopic evaluation. PMN were resuspended to a final concentra-
tion of 5 
 
 
 
 10
 
7
 
 in HBSS with 10 mM Hepes, pH 7.4, and with-
out Ca
 
2
 
 
 
 or Mg
 
2
 
 
 
 (Sigma-Aldrich). PMN were used within 2 h
of isolation.
 
Monoclonal Antibody Production. 
 
KB cell plasma membranes
were used as an antigen to generate a panel of antibodies for func-
tional screening. Plasma membranes were isolated using nitrogen
cavitation (200 psi; 8 min; 4
 
 
 
C) as described previously (14).
Mice was injected intraperitoneally with a 50:50 mix of TiterMax
and KB membrane protein (50 
 
 
 
g). Mice were inoculated every
2 wk for 6 wk with 25 
 
 
 
g KB membranes in sterile PBS. Spleno-
cytes were harvested, washed in PBS, and mixed 2:1 with hybrid-
oma cells in the presence of 50% polyethyleneglycol. Cells were
plated in DMEM supplemented with 1% HAT for selection. Sin-
gle clones were obtained by limiting dilution (920 clones). Cul-
tures of KB cells in 96-well plates were used in an ecto-ELISA to
select for clones producing antibodies to epithelial surface pro-
teins (510 clones). Supernatants from these clones were used in
PMN transmigration assays to select for antibodies that inhibited
transmigration by 50%. Of these, one antibody (subclone OE-1,
IgG2a) was further characterized.
 
Transmigration Assay. 
 
PMN transmigration assays were per-
formed as described previously (15). All epithelial experiments
were performed in the physiologically relevant basolateral-to-
apical direction (i.e., inverted monolayers), unless otherwise in-
dicated, and all HMVEC transmigration studies were performed
in the apical-to-basolateral direction. In brief, 10
 
6
 
 PMN were
added to the upper chambers of transwell inserts in which T84,
KB, or Caco2 cell monolayers, as indicated, were plated on the
opposing side. A chemotactic gradient was established by adding
 
n
 
-formyl-methionyl-leucyl-phenylalanine (fMLP) to the lower
chambers (1 
 
 
 
M for Caco2 and T84 epithelia; 10 nM for KB
cells and HMVEC). PMN transmigration was performed at 37
 
 
 
C
for 1 h with KB and HMVEC monolayers and for 2 h with T84
monolayers. Transmigrated PMN were quantified by assaying
for the PMN azurophilic marker myeloperoxidase as described
previously (16). In brief, transmigrated PMN were lysed by the
addition of Triton X-100 to a final concentration of 0.5%. The
samples were acidified with citrate buffer (final concentration
100 mM, pH 4.2). An aliquot of sample (70 
 
 
 
l) was added to an
equal volume of ABTS solution (1 mM ABTS [2.2
 
 
 
-azino-bis
(3-ethylbenzo-thiazoline-6-sulfonic acid)], 0.03% H
 
2
 
O
 
2
 
, 100 mM
sodium citrate buffer, pH 4.2) in a 96-well plate. The resulting
color was quantitated on a plate reader at 405 nm. For kinetic
transmigration and posttransmigration adhesion assays, monolay-
ers were removed at the desired time point and placed in a new
24-well plate with HBSS and spun at 50
 
 
 
g
 
 for 5 min to dislodge
PMN adherent to the monolayer (6). PMN were quantified by
marker myeloperoxidase assay as described previously in this
paragraph. Where indicated, polyclonal DAF antisera (a gift
from B.P. Morgan, University of Wales, Cardiff, United King-
dom) or control polyclonal platelet-endothelial cell adhesion
molecule (PE-CAM; a gift from J. Bischoff, Children’s Hospital
and Harvard Medical School, Boston, MA) antisera were used to
assess transmigration.
 
PMN Adhesion Assay. 
 
PMN adhesion to confluent T84 epi-
thelial cells was performed using modifications of a previous pro-
tocol (17). In brief, for studies of adhesion, human PMN were
labeled for 30 min at 37
 
 
 
C with 2
 
 
 
7
 
 
 
-bis (carboxyethyl)-5 (6)-
carboxyfluorescein pentaacetoxymethyl ester (BCECF-AM, 5 
 
 
 
M
final concentration; Calbiochem) and washed three times in
HBSS. Epithelial monolayers grown on 24-well plates were pre-
incubated with mAb OE-1 or control W6/32 at indicated con-
centrations for 10 min at 37
 
 
 
C. BCECF-labeled PMN (2 
 
 
 
 10
 
6
 
/
monolayer) were added to washed epithelial monolayers contain-
ing 10 nM fMLP, plates were centrifuged at 150
 
 
 
g
 
 for 4 min to
uniformly settle PMN, and adhesion was allowed for 10 min atT
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37
 
 
 
C. Monolayers were gently washed three times with HBSS,
and fluorescence intensity (excitation, 485 nm; emission, 530 nm)
was measured on a fluorescent plate reader (Cytofluor™ model
2300; Millipore). Adherent cell numbers were determined from
standard curves generated by serial dilution of known PMN
numbers diluted in HBSS. All data were normalized for back-
ground fluorescence by subtraction of fluorescence intensity of
samples collected from monolayers incubated in buffer only,
without addition of PMN.
 
Tryptic Digestion and Identification of OE-1 Antigen. 
 
Bulk Ag
was purified from 
 
 
 
500 cm
 
2
 
 of confluent KB plasma membranes
using OE-1–coupled affinity column (CnBr-activated sepharose
4B; Pierce Chemical Co.) as described previously (13). Antigen
was eluted at low pH (150 mM NaCl, 100 mM glycine/HCl, pH
2.5, containing 1% 
 
n
 
-octylglucoside). The resulting eluant was
pH-neutralized and resolved by SDS-PAGE, and bands were lo-
calized by Coomassie stain. The resulting 
 
 
 
80-kD band (
 
 
 
100
pmol) was extracted and submitted to the Dana Farber Cancer
Institute Peptide Core Facility for trypsin digestion and microse-
quence analysis.
 
Immunofluorescent Staining of Epithelial Monolayers. 
 
Caco2
cells were grown to confluency on membrane permeable filters.
After transmigration, the inserts were fixed for 10 min at room
temperature in 1% paraformaldehyde in cacodylate buffer (0.1 M
sodium cacodylate, pH 7.4, 0.72% sucrose). After washing once
with PBS, the cells were stained for 1 h at room temperature with
a 130-
 
 
 
g/ml monoclonal OE-1, polyclonal anti-DAF (1:100), or
monoclonal anti-CD11b (60 
 
 
 
g/ml; clone 44a). After washing
twice in PBS, the monolayers were incubated with either 1 
 
 
 
g/
ml goat anti–mouse Oregon green or 1 
 
 
 
g/ml goat anti–rabbit
Texas red. Fluorescent secondary antibodies were purchased from
Molecular Probes. Stained inserts were carefully excised and
mounted in polyvinyl alcohol mounting media. Laser Sharp im-
aging software (Bio-Rad Laboratories) was used for confocal im-
aging and processing.
 
Immunoblotting Experiments. 
 
Indicated cells were grown to
confluency on 100 mm plastic petri dishes. The monolayers were
lysed for 10 min in 1 ml lysis buffer (150 mM NaCl, 25 mM Tris,
pH 8.0, 5 mM EDTA, 2% 
 
n
 
-octylglucoside, and 10% mammalian
tissue protease inhibitor cocktail; Sigma-Aldrich), scraped, and
collected into microfuge tubes. After spinning at 14,000 
 
g
 
 to re-
move cell debris, the pellet was discarded. Proteins were solubi-
lized in nonreducing Laemmli sample buffer and heated to 100
 
 
 
C
for 5 min. Samples were resolved on a 10% polyacrylamide gel
and transferred to nitrocellulose membranes. The membranes
were blocked 1 h at room temperature in PBS supplemented
with 0.2% Tween 20 (PBS-T) and 4% BSA. The membranes
were incubated in 3 
 
 
 
g/ml OE-1 in PBS-T for 1 h at room tem-
perature, followed by 10-min washes in PBS-T. The membranes
were incubated in 1:10,000 goat anti–mouse IgG (ICN/Cappel)
and conjugated to horseradish peroxidase for 1 h at room temper-
ature. The wash was repeated, and proteins were detected by en-
hanced chemiluminescence.
 
Sequential Immunoprecipitations. 
 
Cells were grown to conflu-
ency on 100 mm plastic petri dishes. The monolayers were lysed
with 1 ml lysis buffer. Cellular debris was removed by centrifuga-
tion, and the lysates were precleared with 25 
 
 
 
l of a 50% protein
G-sepharose slurry (Amersham Biosciences) for 2 h at 4
 
 
 
C. 20 
 
 
 
g
OE-1 or 20 
 
 
 
g polyclonal anti-DAF was added to 1 ml of lysate,
rotated overnight at 4
 
 
 
C, and subjected to capture with 50 
 
 
 
l of
50% protein G-sepharose slurry. After the protein G-sepharose
beads had been removed, the immunoprecipitation reaction was
repeated two more times to effectively remove the OE-1 antigen.
 
Finally, OE-1 and anti-DAF immunoprecipitated lysates were
subjected to a final immunoprecipitation reaction with anti-DAF
or OE-1 antibody, respectively. The captured antigen from each
immunoprecipitation reaction was washed three times in immu-
noprecipitation wash buffer. After solubilization in Laemmli sam-
ple buffer, protein were resolved by SDS-PAGE and visualized
by Western blotting with OE-1.
 
Differential Biotinylation of Apical and Basolateral Surface Pro-
teins. 
 
T84 cells were grown to confluence on 0.5 
 
 
 
m polycar-
bonate transwell inserts. The monolayers were washed once in
HBSS. Sulfo-NHS-biotin (Pierce Chemical Co.) was diluted in
HBSS to a final concentration of 1 mM and added apically or ba-
solaterally for 10 min at 4
 
 
 
C. The monolayers were washed re-
peatedly with HBSS containing 150 mM NH
 
4
 
CL to quench the
residual biotin. Monolayers were lysed in lysis buffer for 10 min
at 4
 
 
 
C. After removal of cellular debris by centrifugation, 20 
 
 
 
g
OE-1 was added to immunoprecipitate DAF. Biotinylated cell
surface DAF was detected with avidin–horseradish peroxidase
(Pierce Chemical Co.).
 
DAF Suppression Studies. 
 
Caco2 cells were chosen for these
experiments because they are more easily transfected than T84
cells. Confluent Caco2 monolayers were dislodged from T175
flasks with trypsin. Cells were washed once in serum-free
DMEM. 100 
 
 
 
l serum-free media, 10 
 
 
 
l DAF siRNA ribonucle-
otide (20 
 
 
 
M each of sense 5
 
 
 
-AAUUCCUGGCGAGAAG-
GACUCdTdT-3
 
 
 
 and antisense 3
 
 
 
-dTdTUUAAGGACCGCU-
CUUCCUGAG-5
 
 
 
, synthesized by Xeragon, Inc.), or 10 
 
 
 
l
phosphorothioate derivatives of DAF antisense oligonucleotide
(20 
 
 
 
M of 5
 
 
 
-CGTGTCTCAGAGACCGACTT-3
 
 
 
, synthe-
sized by Oligo’s Etc.) was added. In both cases, a control oligonu-
cleotide (5
 
 
 
-ATGGAGGGCGCCGGC-3
 
 
 
) was used in parallel.
To these solutions, 10 
 
 
 
l Superfect transfection reagent (QIAGEN)
was added. The tubes were vortexed and incubated at room tem-
perature for 10 min to allow transfection complexes formation.
After this incubation, 400 
 
 
 
l of serum-containing media was
added to the complexes, followed by 800 
 
 
 
l of cell suspension.
The cells and complexes were mixed well and 80 
 
 
 
l of cell sus-
pension was plated on the underside of each transwell insert. The
inserts were incubated upside down overnight at 37
 
 
 
C in a hu-
midified incubator containing 5% CO
 
2
 
. The following day, the
inserts were flipped into DMEM-containing 20% FBS. Monolay-
ers were used after 4 d of incubation.
 
Phage Panning of OE-1. 
 
The OE-1 binding epitope was ana-
lyzed using phage display (18). In brief, sepharose-coupled OE-1
was incubated with 20 
 
 
 
l aliquots of the random 9-mer LL9
phage library (
 
 
 
5 
 
 
 
 10
 
10
 
 phage) in 1 ml HBSS containing 0.1%
BSA (phage buffer) for 2 h at 4
 
 
 
C or for 1 h at 20
 
 
 
C in a 1.5-ml
microcentrifuge tube as described previously (19). Antibody
complexes were washed five times with phage buffer and bound
phage were eluted for 5 min in 2 ml of 0.1 M glycine, pH 2.2,
followed by the addition of phage buffer containing 0.5% Tween
20 to the remaining cell pellet. After neutralization with Tris
buffer, pH 8.1, the titer of phage was determined in each fraction
by plaque assay according to standard procedures. Phage elutes
were amplified in “starved” K91 
 
Escherichia coli
 
 on solid luria
broth agar containing 75 
 
 
 
g/ml kanamycin, purified by precipi-
tation with polyethylene glycol, and resuspended in 600 
 
 
 
l
NaCl/Hepes buffer. An aliquot (20  L) of purified phage was
subsequently reapplied to a new aliquot of sepharose-coupled
OE-1 for a total of three affinity purification and two amplifica-
tion steps. Individual phage clones were isolated and amplified,
and the random peptide sequences were deduced after sequenc-
ing the unique nucleotide region of the pIII protein. As a controlT
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for OE-1–specific selection, parallel phage affinity purification
steps were performed in a 1.5-ml microcentrifuge tube in the ab-
sence of OE-1, and a sample of the recovered phage was analyzed
by sequencing of the DNA insert. Consensus sequence peptide
(amino acid sequence EVEHWYRSG), as well as scrambled con-
trol peptide (amino acid sequence SPLAQAVRSSSR), was com-
mercially synthesized (BioWorld Inc.) and tested in transmigra-
tion, and OE-1 binding assays were performed as described
earlier in Monoclonal Antibody Production.
In subsets of experiments, peptides were biotinylated (sulfo-
NHS-biotin; Pierce Chemical Co.), purified by reversed-phase
HPLC, and tested for binding to PMN. In brief, PMN (107
PMN in 1 ml) were incubated with biotinylated peptide DAF
peptide or control peptide (each at 10  g/ml) at 4 C for 1 h.
PMN were washed three times in HBSS and incubated with
rhodamine-labeled streptavidin (Roche Diagnostics). Samples
were aliquoted on a 96-well plate, and fluorescence intensity (ex-
citation, 550 nm; emission, 580 nm), expressed as relative fluores-
cence units (RFU), was measured on a fluorescent plate reader
(Cytofluor™ model 2300; Millipore).
Data Analysis.  PMN transmigration and ELISA data were
compared by two-factor analysis of variance (ANOVA) or by
Student’s t test where appropriate. Values are expressed as the
mean and SEM from at least three separate experiments.
Results
Fusion Results.  One fusion of splenocytes from mice
immunized with KB cell membranes yielded 920 antibody-
producing clones. Each clone was screened for reactivity to
intact KB cells and for inhibition of PMN transmigration
across KB cell monolayers. In total, 510 clones were epi-
thelial-reactive and of these, 31 clones significantly influ-
enced PMN transmigration (n   29 inhibited PMN migra-
tion  50%; n   2 promoted PMN migration  50%). Of
these, one subclone (IgG2a, termed clone OE-1), which
inhibited PMN migration in this screen, also bound domi-
nantly to the apical cell surface (see Biochemical Characteriza-
tion of OE-1 Antigen), and as such, was further characterized
as an apical epithelial ligand for PMN.
Functional Characterization of mAb OE-1.  OE-1 was
tested on two epithelial cell lines (KB and T84 cells), and
one nontransformed primary culture of HMVEC to deter-
mine the influence on PMN transmigration. As shown in
Fig. 1, OE-1 significantly inhibited PMN migration in a
concentration-dependent manner (for each, P   0.025 by
ANOVA), with 3  g/ml inhibiting PMN transmigration
by  50% compared with either no mAb (P   0.001) or to
our binding control W6/32 directed against MHC class I
(P   0.01; Fig. 1, A–C).
Recent works have suggested that PMN binding to epi-
thelial bound antibody via surface Fc receptors may influ-
ence PMN trafficking through epithelia (6). To rule out
the involvement of PMN Fc receptor ligation in this activ-
ity, we enzymatically cleaved OE-1 with papain to gener-
ate Fab fragments, and tested such Fab fragments for inhibi-
tion of PMN migration. As shown in Fig. 1 D, Fab
fragments of OE-1 also inhibited PMN transmigration (P  
0.01), indicating that such findings are not likely related to
Fc-mediated interactions with PMN.
Previous papers have indicated that PMN transmigration
across polarized epithelia can vary depending on the direc-
tion of migration (14, 15). As such, we examined whether
OE-1 influenced PMN transmigration in a polarized fash-
ion. Interestingly, inhibition of transmigration by OE-1
was independent of the direction of migration across elec-
trically confluent (TER   1,000   cm2), polarized T84
epithelia. Relative to 10  g/ml mAb control W6/32, 10
 g/ml OE-1 inhibited PMN migration by 69   8% in the
nonphysiologic apical-to-basolateral direction (P   0.01),
and by 73   10% in the physiologically relevant basolat-
eral-to-apical direction (P   0.01). In total, these results
suggest that the OE-1 antigen represents a surface protein
important to successful PMN transmigration across both
endothelial and epithelial cell monolayers.
Biochemical Characterization of OE-1 Antigen.  Next, we
determined the relative nature and localization of OE-1 an-
tigen. Confocal immunolocalization was used to determine
Figure 1. Functional influence of OE-1 on transmigration. Monoclonal
antibody to epithelial surface protein inhibits human neutrophil trans-
migration. PMN migration across T84 monolayers (A, basolateral-to-apical
direction), KB monolayers (B, basolateral-to-apical direction), or HMVEC
monolayers (C, apical-to-basolateral direction) in response to a fMLP gradient
was performed in the presence or absence of indicated concentrations of
intact OE-1, control antibody (W6/32) or Fab fragments (D, KB cell
transmigration, basolateral-to-apical direction). Data are presented as
mean   SEM (n   3).T
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the overall localization on T84 epithelia. As shown in Fig.
2 A, the OE-1 epitope localized exclusively to the apical
membrane surface and to subapical membrane domains of
polarized cells grown on membrane permeable supports.
Localization of the antigen after PMN transmigration in
the presence of OE-1 revealed that the OE-1 epitope re-
mains localized to the apical domain and that PMN (local-
ized with anti-CD11b mAb 44a) appear to “cluster” in dis-
tinct regions on the apical surface in the presence of OE-1
(Fig. 2, B and C). This clustering of PMN is consistent
with previous observations (16), and is likely a result of lo-
calized epithelial barrier disruptions, with resultant in-
creases in flux of chemoattractant.
Western blot analysis of the OE-1 epitope revealed a
heavily glycosylated 70–80-kD protein expressed to vary-
ing degrees on a number of different cell types, including
epithelial cells, endothelial cells, and platelets (Fig. 2 D).
The relatively small differences in apparent molecular
weight between different cell lines likely represents cell tis-
sue–specific differences in glycosylation (20). This antibody
did not Western blot under reducing conditions (unpub-
lished data). Immunoprecipitation of differential surface
biotinylated T84 cells confirmed our confocal localization
results, with nearly exclusive expression demonstrated in
cells labeled from the apical, but not basolateral, surface
(Fig. 2 E). Such results suggest that the OE-1 antigen rep-
resents a heavily glycosylated,  70–80-kD protein expressed
on the apical membrane surface.
Identification of the OE-1 Antigen as DAF.  Next, ex-
periments were performed to identify the antigen recog-
nized by OE-1. Approximately 500 cm2 of confluent KB
cells were used to obtain sufficient quantities of OE-1 anti-
gen for microsequence analysis. The antigen was digested
with trypsin, and seven tryptic peptides resulting from mass
spectroscopy showed direct sequence homology (Fig. 3 A)
with CD55, also termed DAF, a glycoprotein organized
into four homologous short consensus repeats (SCR, also
Figure 2. Localization of OE-1 antigen to the apical surface. (A) Confocal
immunofluorescence was used to define the pattern of OE-1 antigen ex-
pression. Shown here is an x-z orientation series demonstrating nearly
complete localization to the apical and subapical membrane compartment.
(B) An apical confocal section localizing OE-1 (red) with the PMN
marker CD11b/18 (clone 44a, green) after PMN transmigration. C repre-
sents an x-z orientation series of B. In D, equal amounts of lysates from
indicated cell types were resolved on an 10% SDS-PAGE and immuno-
blotted with OE-1. The OE-1 antigen is expressed in varying amounts in
the different cell types. The differences in molecular weights are likely
due to differential glycosylation. Epithelial cell lines (KB, T84) express
the highest levels of OE-1 antigen, followed by cells normally in close
contact with complement proteins (HMVEC, platelets). Primary cell lines
such as OKF6 (keratinocytes) express lesser amounts of the OE-1 antigen.
(E) Confluent T84 monolayers were biotinylated on the apical (Ap) or
basolateral (Bl) surface. Lysates were immunoprecipitated with either an
isotype control antibody (C) or OE-1. Proteins were visualized with avidin-
HRP to identify only surface, biotinylated DAF (left) or with OE-1 to
demonstrate total DAF (right). Lanes labeled “C” represent isotype immuno-
precipitation control samples.
Figure 3. Biochemical identification of OE-1 antigen as human CD55;
decay-accelerating factor (DAF). (A) Tryptic peptides derived from affinity-
purified OE-1 antigen (OE-1 pep) aligned with DAF SCR domains 1–4.
To confirm the identity of the OE-1 antigen as human CD55, IP reactions
were performed. (B) T84 lysates were immunoprecipitated with OE-1
(lane 1) or a polyclonal anti-DAF (lane 2). The resolved proteins were
immunoblotted using OE-1 under nonreducing conditions. Both anti-
bodies immunoprecipitated identical proteins. Lane 3 is cell lysate run as a
marker for DAF. (C) A single lysate was sequentially immunoprecipitated
three times using 5  l of anti-DAF per reaction. The captured protein
from each IP reaction is shown in lanes 1–3. Note diminishing amounts
of DAF recovered in each reaction. After the third reaction, the lysate was
immunoprecipitated with 10  g of OE-1 (lane 4). Lack of a recoverable
protein confirms the identity of the OE-1 antigen as CD55. D is identical
to the experiment in C, except the sequential IPs were first done using
OE-1 and the final IP was done using polyclonal anti-DAF.T
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called complement control protein repeats) classically viewed
as an inhibitor of autologous complement lysis (20). In
support of this identification, and as suggested by our lo-
calization and Western blotting experiments (Fig. 2), DAF
is a heavily glycosylated  70–80-kD protein widely ex-
pressed in many cells and tissue types. In addition, on most
cell types, DAF exists predominantly as a GPI-anchored
protein (20). In support of our apical localization results
(Fig. 2), GPI-anchored proteins are predominantly ex-
pressed only on the apical membrane in polarized epithe-
lial cells (21).
To further confirm the identity of DAF as the OE-1 an-
tigen, we performed immunoprecipitation and immunode-
pletion experiments. As shown in Fig. 3 B, T84 lysates
were immunoprecipitated with either OE-1 (lane 1), or
polyclonal anti-DAF (lane 2). Lane 3 contains platelet ly-
sate as a standard. As can be seen, both immunoprecipita-
tion reactions pull down proteins of a similar molecular
mass and degree of glycosylation. For the immunodeple-
tion experiments, a single lysate was repeatedly immuno-
precipitated with OE-1 (Fig. 3 C), or polyclonal anti-DAF
(Fig. 3 D). Each lysate was immunoprecipitated three times
to deplete the antibody-binding protein, followed by a sin-
gle immunoprecipitation with the opposing antibody
(polyclonal anti-DAF or OE-1, respectively). As can be
seen, the nearly complete absence of signal in the cross im-
munoprecipitation reactions (Fig. 3 C, lane 4 and Fig. 3 D,
lane 4) confirmed that OE-1 and anti-DAF bind to identi-
cal antigens from epithelial lysates. Similarly, as shown in
Fig. 4 A, polyclonal antisera against DAF, but not control
antisera to PE-CAM, inhibited PMN transmigration in a
concentration-dependent manner (P   0.025 by ANOVA).
Together, these studies identify the OE-1 antigen as DAF
and indicate that DAF is an apically localized epithelial
protein that functions, at least in part, to modulate PMN
migration.
Apical DAF Represents an Antiadhesive PMN Ligand.
Next, we determined the functional role of epithelial DAF
in modulation of PMN transmigration. We reasoned that if
DAF is functional from the apical membrane surface of ep-
Figure 4. Role of DAF in the kinetics of PMN
transmigration. (A) Influence of DAF antisera on
PMN transepithelial migration. Epithelia were ex-
posed to indicated concentrations of DAF (black
bars) or control PE-CAM (shaded bars) antisera and
assessed for PMN transmigration. (B and C) The
influence of OE-1 (dashed line) or control W6/32
(solid line) on the kinetics of transmigration was
assessed. B represents the number of PMN that
completely traverse the epithelial monolayer and C
represents the number of PMN that remain attached
to the apical epithelial membrane. Data are pre-
sented as mean   SEM (n   4). (D) The influence
of indicated concentrations of mAb OE-1 or control
mAb W6/32 on fMLP-stimulated PMN adhesion
to confluent T84 cells was assessed. Data are presented
as mean   SEM (n   4).T
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ithelia, it may represent a terminal step in PMN migration,
and as such, may contribute significantly to the kinetics of
PMN accumulation at the apical membrane domain. Three
approaches were used to define these principles. First, we
examined the influence of OE-1 on the kinetics of PMN
transmigration. To do this, we used an approach described
previously that quantitates PMN migration from the same
set of monolayers over blocks of time (6, 22). In our exper-
iments, we assessed PMN every 30 min over a 2-h period.
As shown in Fig. 4 B, compared with control W6/32, the
presence of OE-1 significantly slowed PMN transmigration
across T84 epithelial monolayers (P   0.01 by ANOVA).
Significant differences were observed as early as 30–60 min,
and were evident as late as 150 min (unpublished data).
More importantly, this decrease in PMN transmigration
shown in Fig. 4 B was almost completely explained by ac-
cumulation of PMN on the apical surface of epithelia (Fig.
4 C). Indeed, as early as 30–60 min, the number of apical
PMN increased significantly in the presence of OE-1 (P  
0.05 compared with W6/32) and remained elevated through
the 120-min period. Such findings indicate that rather than
inhibiting PMN transmigration, OE-1 promotes the apical
accumulation of PMN on epithelia.
Second, we reasoned that if DAF functions as antiadhesive
molecule, then OE-1 should promote adhesion to the apical
surface of epithelia. To test this idea, epithelial-PMN adhe-
sion assays were performed. As shown in Fig. 4 D, preincu-
bation of epithelia with increasing concentrations of OE-1
and determination of fMLP-stimulated PMN adhesion re-
vealed that OE-1 increases PMN adhesion in a concentra-
tion-dependent fashion (P    0.025 by ANOVA). Such
findings were not related to Fc receptor–mediated adhesion,
because isotype control antibodies (clone W6/32) resulted in
no significant increase in adhesion (P   not significant).
As a third approach, we used antisense oligonucleotides
and siRNA technologies to diminish surface expressed
DAF and examined the kinetics of PMN migration across
such monolayers of epithelia. As determined by immuno-
precipitation of surface-biotinylated protein (Fig. 5 A), an-
tisense oligonucleotides and siRNA decreased surface ex-
pressed DAF by 68   10% and 63   12% relative to
oligonucleotide controls (n     3 determinations). Using
cells treated in this manner, we assessed transmigration and
apical PMN accumulation. As shown in Fig. 5 B, PMN
transmigration across both antisense and siRNA exposed
cells was significantly diminished relative to either mock-
treated or oligonucleotide control–treated monolayers (P  
0.025 for both by ANOVA). Diminished PMN transmi-
gration in DAF-depleted cells was less obvious when mea-
sured at early time points, and became most apparent be-
yond 90 min. Conversely, as shown in Fig. 5 C, assessment
of apical PMN in DAF-depleted epithelia revealed a signif-
icant increase over time in a manner similar to mAb OE-1
exposure (P   0.05 for both by ANOVA). In addition, we
Figure 5. Influence of DAF depletion on
PMN transmigration. (A) Representative Western
blot analysis of total cellular DAF protein in
Caco2 cells exposed to mock conditions (trans-
fection loading reagent only), control oligo-
nucleotide, DAF antisense oligonucleotide, or
DAF siRNA. (B and C) The influence of
siRNA (diamonds) and antisense oligonucleotide
(squares) on the kinetics of transmigration was
assessed. B represents the number of PMN that
completely traverse the epithelial monolayer
and C represents the number of PMN that remain
attached to the apical epithelial membrane. Also
shown are mock conditions (closed circles) and
oligonucleotide control conditions (crosses).
Data are presented as mean   SEM (n   4).
(D) Immunofluorescence photomicrographs of
PMN (green, localization of CD11b/18 with
44a) at the epithelial apical surface after trans-
migration in monolayers loaded with siRNA,
antisense oligonucleotide (AS), or mock treat-
ment. Decreased DAF expression (red, localiza-
tion with OE-1) is associated with increased
PMN clustering on the apical surface of epithelia
(compare density of clusters in mock vs.
siRNA/AS conditions).T
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determined whether is was possible to distinguish such bio-
chemical differences at the morphological level. As shown
in Fig. 5 D, confocal localization of PMN in mock and an-
tisense/siRNA-treated monolayers after transmigration re-
vealed increased PMN represented as large aggregations of
PMN particularly prominent on the apical surface of DAF-
depleted epithelia. Together, these results support our find-
ings with mAb OE-1 and suggest that DAF represents an
apically localized, antiadhesive PMN ligand that signifi-
cantly influences the kinetics of PMN trafficking through
epithelial monolayers.
Phage Display Mapping of the OE-1 Binding Epitope.
Next, we extended these findings to determine the OE-1–
binding epitope. Initially, we used OE-1–based Western
blotting to screen Chinese hamster ovary (CHO) transfec-
tants expressing wild-type human DAF and truncations of
DAF SCR domains 1–4, as described previously (23). As
shown in Fig. 6 A, these studies revealed the loss of OE-1
reactivity in only the SCR-3 truncation. Loss of SCR-3
was not due to diminished overall DAF expression, as de-
termined by blotting of total DAF content using polyclonal
anti-DAF antisera. Such findings suggest that OE-1 recog-
nizes an epitope encoded, at least in part, by the SCR-3
domain of DAF.
To better define the DAF epitope recognized by OE-1,
we used the LL9 phage library characterized previously dis-
playing linear 9-mer peptides to select for OE-1 binding
epitopes (19). The library underwent three rounds of pan-
ning over bound OE-1 with intermediate amplifications.
The round 3–enriched phage had a titer of 5.0   109
PFU/ml and yielded an enrichment of  3 logs relative to
round 1. As shown in Fig. 6 B, 13 phage clones were se-
quenced; aligned sequences revealed a number of structural
similarities. In particular, a pattern amino acid sequence of
EXEX*WXXX** (where X is neutral, X* is large, and X**
is hydrophobic) emerged as a relatively close consensus
match. Based on our analysis of DAF, and consistent with
our observations that OE-1 does not Western blot under
reducing conditions, this linear sequence did not exist in
SCR domain 3. These findings suggest that OE-1 recog-
nizes a nonlinear constrained epitope where, at least in part,
SCR-3 contributes to this binding.
As shown in Fig. 6, a synthetic peptide corresponding to a
best-fit OE-1 epitope consensus (EVEHWYRSG), but not
a scrambled peptide, blocked OE-1 binding to denatured
protein (Fig. 6 C, Western blot) and to the intact epithelial
cell surface protein (Fig. 6 D, ELISA) in a concentration-
dependent manner, suggesting that this EVEHWYRSG pep-
tide is a least a reasonable match for the OE-1 epitope. In its
labeled form (biotin-EVEHWYRSG), binding to the sur-
face of intact PMN was readily detectable (fluorescence in-
tensity, 2,188   383 RFU, n   4) compared with either la-
beled control peptide (fluorescence intensity, 81   12 RFU,
P   0.01 compared with biotin-EVEHWYRSG) or to un-
labeled peptide (fluorescence intensity, 33   6 RFU, P  
0.01 compared with biotin-EVEHWYRSG).
Next, we determined whether this synthetic peptide in-
fluenced the PMN transmigration and accumulation of
PMN on the surface of epithelia after transmigration. As
shown in Fig. 7, PMN and epithelial preexposure to in-
creasing concentrations of EVEHWYRSG, but not scram-
bled peptide, resulted in both increased apical accumulation
of PMN (Fig. 7 A, P   0.025 by ANOVA) and diminished
PMN transmigration (P   0.05 by ANOVA). Such data
Figure 6. SCR domain mapping and identification
of OE-1 epitope. (A) Lysates from CHO cell mutants
expressing DAF with individual SCR domains deleted
were used to map which SCR domain contained the
OE-1 epitope. Lysates were resolved by SDS-PAGE
and immunoblotted with OE-1 (top) or polyclonal
DAF antisera (bottom) to assess total DAF. (lanes)
CHO, unaltered CHO cells; DAF, CHO cells expressing
full length DAF;  1–4, CHO cells expressing DAF
with the corresponding SCR domain deleted. OE-1
does not recognize SCR-3 domain deletion. B represents
13 phage sequences and an overall consensus sequence
eluted from three rounds of panning with OE-1–coupled
sepharose. (B and C) OE-1 mAb was incubated with
indicated concentrations of synthetic EVEHWYRSG
peptide, or a control scrambled peptide (Scr), and used
to probe Western blots from T84 epithelial lysates (C)
or cell surface ELISA on intact T84 cells. Data are
presented as mean   SEM (n   3).T
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support our OE-1 findings and suggest that we can recapit-
ulate this biology with a closely matched synthetic mimetic
corresponding to the OE-1 epitope.
Discussion
Transepithelial migration of PMN is the pathological
hallmark of active mucosal inflammation and occurs in
such disease states as inflammatory bowel disease, peri-
odontitis, cystitis, and infectious enterocolitis (24). Before
movement through the interstitium to the epithelium,
PMN first escape the vasculature through a distinct, well-
characterized set of interactions with the endothelium. Less
is known about leukocyte interactions with epithelial cells.
We report here that CD55 represents an apical, antiadhe-
sive ligand for PMN during transmigration.
The current paradigm for transmigration of PMN across
epithelial monolayers envisions a process consisting of
sequential molecularly defined events, including initial
CD11b/18-mediated interactions of PMN with epithelia
(24, 25). Unlike endothelial cells, a number of papers using
diverse epithelial models have demonstrated that ICAM-1
is not an epithelial ligand for PMN  2 integrins (5, 15, 16,
26, 27), although under some conditions, ICAM-1 may
function as an apical anchor for PMN (5). Functional map-
ping studies of this  2 integrin–dependent pathway have
suggested that the profile of inhibition is distinct from that
of other known ligands of CD11b/CD18 (28). Subsequent
CD47-mediated orchestration of PMN movement through
the paracellular space is now a well-accepted principle (24).
Apical ligands for PMN are less well understood, and for
that reason, we sought to better define the existence of api-
cal PMN ligands on epithelia. A monoclonal strategy was
used that screened based on criteria as follows: (a) epithelial
surface binding, (b) modulation of PMN migration, and (c)
localization to the apical membrane. This strategy identi-
fied OE-1 and was demonstrated to bind and regulate
PMN migration across diverse epithelial monolayers, in-
cluding nontransformed cell types (e.g., HMVEC).
Immunopurification and microsequencing identified the
OE-1 ligand as DAF. Although most analyses of DAF
function have focused on inhibition of complement-medi-
ated lysis, it is important to note that DAF also has non-
complement ligands (29). For example, DAF is an estab-
lished ligand for CD97 on leukocytes. Our studies here
revealed that DAF functions to modulate the rate of PMN
dislocation from the apical epithelial membrane, and as
such, serves as an antiadhesive terminal step in the PMN
transmigration process. Of note, some experiments indi-
cated that mAb OE-1 also inhibited PMN transmigration
in the nonphysiologic direction (apical-to-basolateral), and
by inference, this observation suggests that DAF is a critical
control point for movement of PMN through the paracel-
lular space. These findings of DAF as an antiadhesive mole-
cule are consistent with some previous observations in
other models. For example, King et. al. screened a panel of
antibodies and concluded that DAF, among other surface
molecules, functions to inhibit adhesion of T cells to mac-
rophage-like cells (30). In a more physiologic context, Ver-
bakel et al. demonstrated that human DAF expressed in the
rat heart functioned effectively as an antiadhesive molecule
(31). Clearly, this idea was supported by evidence that OE-1
promotes direct PMN–epithelial adhesion, and peptides
representing the OE-1 epitope appear to promote PMN
accumulation. The idea of antiadhesive molecules has not
been widely studied, and surprisingly little is known about
the de-adhesion state of integrins during the process of
transmigration. Some evidence indicates that the major
leukocyte sialoglycoprotein CD43 may function in de-
adhesive interactions of leukocytes with parenchymal cells,
and as such, may counterbalance a number of proadhesive
integrin functions (30, 32–34). In addition, previous work
has indicated that integrin avidity is both activatable and
transient, thereby providing a cycle of adhesion and de-
adhesion (35–37). Finally, elegant work in the past has in-
dicated that calcineurin may critically regulate integrin
binding to matrix components through transient control of
intracellular Ca2  levels (38).
The present findings indicate that DAF may regulate the
overall kinetics of PMN movement through the epithe-
lium. Of interest, the paracellular PMN ligand CD47 also
functions in a kinetic manner. For example, it was
shown  recently that whereas monoclonal antibodies di-
rected against CD47 delay transepithelial migration, with
time, this anti-CD47 influence is overcome (22). Such sur-
face CD47 function was linked to as yet undefined tyrosine
Figure 7. Influence of OE-1
peptide mimetic on the kinetics
of PMN transmigration. PMN
and the apical reservoir of epi-
thelia were incubated with indi-
cated peptides before coincubation
and assessment of transmigration.
(A and B) The influence of indi-
cated concentrations of OE-1
peptide (EVEHWYRSG, dashed
line), or a scrambled control
(solid line), on the kinetics of
transmigration was assessed. (A)
The number of PMN that remain
attached to the apical epithelial
membrane is shown. (B) The
number of PMN that completely
traverse the epithelial monolayer
is shown. Data are presented as
mean   SEM (n   3).T
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phosphorylation events, suggesting a critical kinetic signal-
ing pathway influencing the rate of PMN migration. In ad-
dition, recent works suggest that transmembrane CD47 sig-
naling function may function, at least in part, in concert
with signal regulatory protein-  (SIRP ), a cell surface
protein containing three immunoglobulin superfamily do-
mains and intracellular immunoreceptor tyrosine-based in-
hibitory motifs (39). CD47 is a ligand for Sirp  (40), and
analyses have suggested that CD47 function is proportional
to the expression of Sirp  and that Sirp  interactions with
CD47 binding may mediate cell–cell interactions (40).
At present, we do not know the PMN ligand for epithe-
lially expressed DAF. Results using biotinylated peptide
corresponding to the OE-1 epitope readily bound to PMN
(Results), suggesting that the OE-1–binding region in DAF
is conformationally similar to a PMN binding site. As al-
luded to in a previous paragraph, a number of papers have
indicated that CD97, a recently identified seven-span trans-
membrane (7-TM) protein expressed by a variety leuko-
cytes early after activation, is a counter-receptor for DAF
(41–43), and these interactions have been profiled in a
number of diseases (44–46). Analyses of structure–function
relationships have indicated that CD97–DAF interactions
represent a Ca2 -dependent, low affinity interaction (47);
that CD97 interacts with the NH2 terminal SCR-1 domain
on DAF (41); that at least three tandemly linked EGF do-
mains on CD97 are necessary for DAF interactions (42);
and that larger splice variants of CD97 (containing more
than three EGF repeats) have a significantly lower affinity
for DAF (42). Our attempts to block either PMN transmi-
gration or apical clustering of PMN with functionally in-
hibitory anti-CD97 mAb (e.g., clone VIM3b) in this model
have not resulted in differences compared with control an-
tibodies (unpublished data). A number of important consid-
erations may contribute to the lack of influence of anti-
CD97 in our model. First, CD97-DAF may be a low
enough affinity that we are not able to detect the relative
importance of CD97 within our system. Second, it is possi-
ble that accessory molecules not expressed on epithelial
may be necessary for CD97–DAF interactions. For in-
stance, our studies define a relative importance for the
SCR-3 domain of DAF (Fig. 6). Recent work with epithe-
lial DAF has suggested that a close extracellular spatial inter-
action exists between DAF SCR-3 and ICAM-1, and that
such an association may limit accessibility to DAF SCR-3
(48). However, this is unlikely because we have reported
previously that in unmodulated epithelia (such as those used
here), ICAM-1 is either absent or expressed at very low
levels (5, 49). Third, and more likely, other DAF ligands
may exist. Our studies with CHO transfectants suggested a
relative importance of SCR-3 in epithelial DAF interac-
tions with PMN, and as alluded to in previous paragraphs,
others have shown that SCR-1 is likely most important for
CD97 interactions (41). As such, additional work will be
necessary to define details of this interaction and/or the ex-
istence of additional DAF ligands expressed on PMN.
Studies directed at identifying OE-1 epitopes revealed
that cells expressing truncations of DAF SCR domain 3 did
not bind OE-1, suggesting that this mAb recognizes SCR-3
and presumably, that SCR-3 is critical for PMN–DAF
interactions. In addition, phage display identified a func-
tional peptide (EVEHWYRSG) corresponding to the OE-1
binding site with a core consensus EXEX*WXXX**
(where X is neutral, X* is large and X** is hydrophobic).
The peptide mimetic used here (amino acid sequence
EVEHWYRSG) bound to the surface of PMN, blocked
both antibody binding to DAF (Western blot and ELISA),
and inhibited transmigration functional responses mediated
by epithelial DAF. Consistent with our findings that the
OE-1 mAb recognizes a conformationally constrained
epitope (e.g., OE-1 does not Western blot reduced DAF),
this consensus peptide sequence does not exist in the pri-
mary structure of DAF. This is not surprising because
phage can also recognize complex, discontinuous epitopes
(18). Our attempts to define conformational epitopes cor-
responding to the OE-1 binding site using a disulfide-con-
strained 10-mer library resulted in no specific phage ampli-
fication or selection (unpublished data), suggesting that the
OE-1 peptide represents a discontinuous epitope on DAF.
Again, this is not surprising given the complex structure of
membrane DAF. The four SCR domains are connected in
series with each domain bearing two loops interconnected
by two disulfide bonds (20). Although we do not know the
exact mechanism by which this peptide mimetic functions
to modulate PMN–epithelial interactions, we presume that
binding to a conformational ligand on PMN occupies a site
important for PMN binding to DAF SCR-3. Alternatively,
this peptide could act indirectly through interactions with
an accessory molecule important in DAF SCR-3 function
(e.g., ICAM-1). For the reasons stated, and evidence that
ICAM-1 has minimal influences on PMN–epithelial inter-
actions without preexposure to proinflammatory stimuli
(e.g., IFN- , pathogenic bacteria; references 4, 5), this lat-
ter example is not likely to contribute significantly to our
observations here.
In conclusion, we demonstrate here that epithelial DAF
represents an apical ligand for PMN during transmigration.
Moreover, these studies identify a peptide mimetic with
potential in disruption of this natural epithelial–PMN in-
teraction. Such insights offer hope in potential therapeutic
development for inflammatory conditions. For example,
surfaces lined by columnar epithelial cells (e.g., those of the
airway and intestine) offer a potential advantage for therapy
in that these surfaces are directly and immediately available
for topical rather than systemic administration of locally ac-
tive therapeutic compounds. It is known that transepithelial
migration of PMN often parallels the degree of patient ill-
ness during acute inflammatory events. For example, inter-
actions of PMN with the apical membrane of intestinal
crypt cells likely have specific influences on epithelial ion
transport; yet to interface with this apical membrane
domain, transepithelial migration is required. Similarly, a
variety of cytokine-specific effects on PMN–epithelial in-
teractions likely modulate the biological sequellae of PMN–
epithelial interactions postvascular emigration. The findings
reported here raise the possibility that delivery of lumenalT
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therapeutic compounds targeted to DAF-based PMN–epi-
thelial recognition sites might represent a future avenue for
local, site-specific, and nonsystemic interventions in in-
flammatory disorders involving selected mucosal sites.
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